Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Epivir
Epivir 150 mg film-coated tablets Epivir 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-085834 · Präparat HOS-083204
The possibility of interactions with other medicinal products administered concurrently should be
considered, particularly when the main route of elimination is active renal secretion via the organic
cationic transport system e.g. trimethoprim. Other medicinal products (e.g. ranitidine, cimetidine) are
eliminated only in part by this mechanism and were shown not to interact with lamivudine. The
nucleoside analogues (e.g. didanosine) like zidovudine, are not eliminated by this mechanism and are
unlikely to interact with lamivudine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) ranitidine (HOS-085660) cimetidine (HOS-085835) didanosine (HOS-085836) zidovudine (HOS-085837)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-20T14:36:00Z · SHA-256 dda482a8b09324ebc742f0589dd9c287ef99dfaee8f30a2889bc848f23ef2100 · Passage f95f33741513a03415ee49d3475d877bb6b9081af94776eebfc6141682077199 · Zeichen 851–1387 im Abschnitt
Wechselwirkungen · Epivir
Epivir 10 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 21
HOS-085872 · Präparat HOS-083204
The possibility of interactions with other medicinal products administered concurrently should be
considered, particularly when the main route of elimination is active renal secretion via the organic
cationic transport system e.g. trimethoprim. Other medicinal products (e.g. ranitidine, cimetidine) are
eliminated only in part by this mechanism and were shown not to interact with lamivudine. The
nucleoside analogues (e.g. didanosine) like zidovudine, are not eliminated by this mechanism and are
unlikely to interact with lamivudine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): didanosine (HOS-085836) zidovudine (HOS-085837) trimethoprim (HOS-085184) ranitidine (HOS-085660) cimetidine (HOS-085835)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-20T14:36:00Z · SHA-256 dda482a8b09324ebc742f0589dd9c287ef99dfaee8f30a2889bc848f23ef2100 · Passage f95f33741513a03415ee49d3475d877bb6b9081af94776eebfc6141682077199 · Zeichen 851–1387 im Abschnitt
Wechselwirkungen · Combivir
Combivir 150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-088512 · Präparat HOS-083663
Drugs by Therapeutic Area
Interaction Recommendation
Geometric mean change (%) concerning co-
(Possible mechanism) administration
ANTIRETROVIRAL MEDICINAL PRODUCTS
Didanosine/Lamivudine Interaction not studied. No dosage adjustment
necessary.
Didanosine /Zidovudine Interaction not studied.
Stavudine/Lamivudine Interaction not studied. Combination not
Stavudine/Zidovudine In vitro antagonism of anti-HIV recommended.
activity between stavudine and
zidovudine could result in
decreased efficacy of both
drugs.
ANTI-INFECTIVE PRODUCTS
Atovaquone/Lamivudine Interaction not studied. As only limited data available
Atovaquone/Zidovudine Zidovudine AUC 33% the clinical significance is
(750 mg twice daily with Atovaquone AUC unknown.
food/200 mg thrice daily)
Clarithromycin/Lamivudine Interaction not studied. Separate administration of
Clarithromycin/Zidovudine Zidovudine AUC 12% Combivir and clarithromycin
(500 mg twice daily/100 mg by at least 2 hours
every 4 hours)
Trimethoprim/sulfamethoxazole Lamivudine: AUC 40% No Combivir dosage
(Co-trimoxazole)/Lamivudine adjustment necessary, unless
(160 mg/800 mg once daily for Trimethoprim: AUC patient has renal impairment
5 days/300 mg single dose) Sulfamethoxazole: AUC (See Section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): didanosine (HOS-085836) stavudine (HOS-088080) atovaquone (HOS-086266) clarithromycin (HOS-084517) trimethoprim (HOS-085184) sulfamethoxazole (HOS-084533)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-29T01:24:00Z · SHA-256 4660d55c0813c2571a95614bba44492fff03e6854bbe956eb43509fe476e679d · Passage ef0dd78ec8fb1f808137e8f5128b1cd7fa4540efa9cc39a15103836ffbdd97d9 · Zeichen 1146–3116 im Abschnitt
Wechselwirkungen · Trizivir
TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-108560 · Präparat HOS-093047
Drugs by Therapeutic Area Interaction Recommendation
Geometric mean change concerning co-
(%) administration
(Possible mechanism)
ANTIRETROVIRAL MEDICINAL PRODUCTS
Didanosine/Abacavir Interaction not studied. No dosage adjustment
Didanosine/Lamivudine Interaction not studied. necessary.
Didanosine/Zidovudine Interaction not studied.
Stavudine/Abacavir Interaction not studied. Combination not
Stavudine/Lamivudine Interaction not studied. recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): didanosine (HOS-085836) stavudine (HOS-088080)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T14:10:00Z · SHA-256 0fa44d429f9cace08dce2fd9d8c4f2ed838fc8cb0ed1b7cfc79bd6b9caa26349 · Passage 25e2eda4712b7995d43a3cb14050be9aa438e6a4898bdc14db6c4e7477aa31e8 · Zeichen 1694–2450 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 11
HOS-112069 · Präparat HOS-093615
The mechanism of interaction between
atazanavir and ritonavir is CYP3A4
inhibition.
Indinavir Indinavir is associated with indirect Co-administration of REYATAZ
unconjugated hyperbilirubinaemia due to and indinavir is not recommended
inhibition of UGT. (see section 4.4).
Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)
Lamivudine 150 mg twice daily No significant effect on lamivudine and Based on these data and because
+ zidovudine 300 mg twice daily zidovudine concentrations was observed. ritonavir is not expected to have a
(atazanavir 400 mg once daily) significant impact on the
pharmacokinetics of NRTIs, the co-
administration of these medicinal
products and REYATAZ is not
expected to significantly alter the
exposure of the co-administered
medicinal products.
Abacavir The co-administration of abacavir and
REYATAZ is not expected to significantly
alter the exposure of abacavir.
Didanosine (buffered tablets) Atazanavir, simultaneous administration Didanosine should be taken at the
200 mg/stavudine 40 mg, both with ddI+d4T (fasted) fasted state 2 hours after
single dose Atazanavir AUC: ↓87% (↓92% ↓79%) REYATAZ taken with food. The
(atazanavir 400 mg single dose) Atazanavir Cmax: ↓89% (↓94% ↓82%) co-administration of stavudine with
Atazanavir Cmin: ↓84% (↓90% ↓73%) REYATAZ is not expected to
significantly alter the exposure of
Atazanavir, dosed 1 hr after ddI+d4T stavudine.
(fasted)
Atazanavir AUC: ↔3% (↓36% ↑67%)
Atazanavir Cmax: ↑12% (↓33% ↑18%)
Atazanavir Cmin: ↔3% (↓39% ↑73%)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521) indinavir (HOS-084518) lamivudine (HOS-085829) zidovudine (HOS-085837) abacavir (HOS-088077) didanosine (HOS-085836) stavudine (HOS-088080)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage e16bb7b3c75a72e29e2846a95fde7bf075f1035a1823dc0170957041762fa37d · Zeichen 9816–12649 im Abschnitt
Wechselwirkungen · Kivexa
Kivexa 600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-113477 · Präparat HOS-093937
Drugs by Therapeutic Area Interaction Recommendation concerning
Geometric mean change (%) co-administration
(Possible mechanism)
ANTIRETROVIRAL MEDICINAL PRODUCTS
Didanosine /Abacavir Interaction not studied. No dosage adjustment
Didanosine/Lamivudine Interaction not studied. necessary.
Zidovudine/Abacavir Interaction not studied
Zidovudine/Lamivudine Lamivudine: AUC
Zidovudine 300 mg single dose Zidovudine : AUC
Lamivudine 150 mg single dose
Emtricitabine/Lamivudine Due to similarities, Kivexa
should not be administered
concomitantly with other
cytidine analogues, such as
emtricitabine.
ANTI-INFECTIVE PRODUCTS
Trimethoprim/sulfamethoxazole Interaction not studied. No Kivexa dosage adjustment
(Co-trimoxazole)/Abacavir necessary.
Trimethoprim/sulfamethoxazole Lamivudine: AUC 40%
(Co-trimoxazole)/Lamivudine When concomitant
(160 mg/800 mg once daily for Trimethoprim: AUC administration with
5 days/300 mg single dose) Sulfamethoxazole: AUC co-trimoxazole is warranted,
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): didanosine (HOS-085836) zidovudine (HOS-085837) emtricitabine (HOS-085840) trimethoprim (HOS-085184) sulfamethoxazole (HOS-084533)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T12:00:00Z · SHA-256 014b022d5230b58f7efa74f9573b1c2e42d28f6a3d171aa8848bc0f8c92c1380 · Passage 3b23f2886f7d80d744304e64283fcb23c64e14afd5a52f5e8622a5373e4f7cc1 · Zeichen 1544–3217 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 11–12
HOS-116342 · Präparat HOS-094447
11
Raltegravir Some clinical studies suggest raltegravir At present the effect of raltegravir
may cause a modest decrease in on darunavir plasma
darunavir plasma concentrations. concentrations does not appear to
be clinically relevant. Boosted
PREZISTA and raltegravir can be
used without dose adjustments.
Nucleo(s/t)ide reverse transcriptase inhibitors (NRTIs)
Didanosine didanosine AUC ↓ 9% Boosted PREZISTA and
400 mg once daily didanosine Cmin ND didanosine can be used without
didanosine Cmax ↓ 16% dose adjustments.
darunavir AUC ↔ Didanosine is to be administered
darunavir Cmin ↔ on an empty stomach, thus it
darunavir Cmax ↔ should be administered 1 hour
before or 2 hours after boosted
PREZISTA given with food.
Tenofovir disoproxil tenofovir AUC ↑ 22% Monitoring of renal function may
245 mg once daily‡ tenofovir Cmin ↑ 37% be indicated when boosted
tenofovir Cmax ↑ 24% PREZISTA is given in
#
darunavir AUC ↑ 21% combination with tenofovir
#
darunavir Cmin ↑ 24% disoproxil, particularly in patients
# with underlying systemic or renal
darunavir Cmax ↑ 16%
disease, or in patients taking
(↑ tenofovir from effect on MDR-1
nephrotoxic agents.
transport in the renal tubules)
PREZISTA co-administered with
cobicistat lowers the creatinine
clearance. Refer to section 4.4 if
creatinine clearance is used for
dose adjustment of tenofovir
disoproxil.
Emtricitabine/tenofovir Tenofovir alafenamide ↔ The recommended dose of
alafenamide Tenofovir ↑ emtricitabine/tenofovir
alafenamide is 200/10 mg once
daily when used with boosted
PREZISTA.
Abacavir Not studied. Based on the different Boosted PREZISTA can be used
Emtricitabine elimination pathways of the other NRTIs with these NRTIs without dose
Lamivudine zidovudine, emtricitabine, stavudine, adjustment.
Stavudine lamivudine, that are primarily renally
Zidovudine excreted, and abacavir for which PREZISTA co-administered with
metabolism is not mediated by CYP450, cobicistat lowers the creatinine
no interactions are expected for these clearance. Refer to section 4.4 if
medicinal compounds and boosted creatinine clearance is used for
PREZISTA. dose adjustment of emtricitabine or
lamivudine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): emtricitabine (HOS-085840) tenofovir alafenamide (HOS-110476) creatinine (HOS-086273) raltegravir (HOS-086187) didanosine (HOS-085836) tenofovir disoproxil (HOS-108843) tenofovir (HOS-088083) cobicistat (HOS-088111) abacavir (HOS-088077) lamivudine (HOS-085829) zidovudine (HOS-085837) stavudine (HOS-088080)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 512d9066057a9fd93eb4b013c0f43af18ef8a6621ab7ae5b2a63872300e65b37 · Zeichen 8755–13360 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 53–54
HOS-116511 · Präparat HOS-094447
53
Nucleo(s/t)ide reverse transcriptase inhibitors (NRTIs)
Didanosine didanosine AUC ↓ 9% PREZISTA co-administered with
400 mg once daily didanosine Cmin ND low dose ritonavir and didanosine
didanosine Cmax ↓ 16% can be used without dose
darunavir AUC ↔ adjustments.
darunavir Cmin ↔ Didanosine is to be administered
darunavir Cmax ↔ on an empty stomach, thus it
should be administered 1 hour
before or 2 hours after
PREZISTA/ritonavir given with
food.
Tenofovir disoproxil tenofovir AUC ↑ 22% Monitoring of renal function may
245 mg once daily‡ tenofovir Cmin ↑ 37% be indicated when PREZISTA
tenofovir Cmax ↑ 24% co-administered with low dose
#
darunavir AUC ↑ 21% ritonavir is given in combination
#
darunavir Cmin ↑ 24% with tenofovir disoproxil,
# particularly in patients with
darunavir Cmax ↑ 16%
underlying systemic or renal
(↑ tenofovir from effect on MDR-1
disease, or in patients taking
transport in the renal tubules)
nephrotoxic agents.
Emtricitabine/tenofovir Tenofovir alafenamide ↔ The recommended dose of
alafenamide Tenofovir ↑ emtricitabine/tenofovir
alafenamide is 200/10 mg once
daily when used with PREZISTA
with low dose ritonavir.
Abacavir Not studied. Based on the different PREZISTA co-administered with
Emtricitabine elimination pathways of the other NRTIs low dose ritonavir can be used
Lamivudine zidovudine, emtricitabine, stavudine, with these NRTIs without dose
Stavudine lamivudine, that are primarily renally adjustment.
Zidovudine excreted, and abacavir for which
metabolism is not mediated by CYP450,
no interactions are expected for these
medicinal compounds and PREZISTA
co-administered with low dose ritonavir.
Non-nucleo(s/t)ide reverse transcriptase inhibitors (NNRTIs)
Efavirenz efavirenz AUC ↑ 21% Clinical monitoring for central
600 mg once daily efavirenz Cmin ↑ 17% nervous system toxicity associated
efavirenz Cmax ↑ 15% with increased exposure to
#
darunavir AUC ↓ 13% efavirenz may be indicated when
#
darunavir Cmin ↓ 31% PREZISTA co-administered with
# low dose ritonavir is given in
darunavir Cmax ↓ 15%
combination with efavirenz.
(↑ efavirenz from CYP3A inhibition)
(↓ darunavir from CYP3A induction)
Efavirenz in combination with
PREZISTA/ritonavir 800/100 mg
once daily may result in
sub-optimal darunavir Cmin. If
efavirenz is to be used in
combination with
PREZISTA/ritonavir, the
PREZISTA/ritonavir 600/100 mg
twice daily regimen should be used
(see section 4.4).
Etravirine etravirine AUC ↓ 37% PREZISTA co-administered with
100 mg twice daily etravirine Cmin ↓ 49% low dose ritonavir and etravirine
etravirine Cmax ↓ 32% 200 mg twice daily can be used
darunavir AUC ↑ 15% without dose adjustments.
darunavir Cmin ↔
darunavir Cmax ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): abacavir (HOS-088077) lamivudine (HOS-085829) zidovudine (HOS-085837) stavudine (HOS-088080) tenofovir alafenamide (HOS-110476) didanosine (HOS-085836) ritonavir (HOS-084521) tenofovir disoproxil (HOS-108843) tenofovir (HOS-088083) emtricitabine (HOS-085840) efavirenz (HOS-087947) etravirine (HOS-088088)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage f8ead3f953777de3c19f091bf055bc5528212e16095144f2b7b3940946af839d · Zeichen 6411–12375 im Abschnitt
Wechselwirkungen · Intelence
INTELENCE 25 mg tablets INTELENCE 100 mg tablets INTELENCE 200 mg tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-119733 · Präparat HOS-095005
Table 2: Interactions and dose recommendations with other medicinal products
Medicinal products by Effects on drug levels Recommendations
therapeutic areas Least Squares Mean Ratio concerning
(90% CI; 1.00 = No effect) co-administration
ANTI-INFECTIVES
Antiretrovirals
NRTIs
Didanosine didanosine No significant effect on
400 mg once daily AUC ↔ 0.99 (0.79-1.25) didanosine and etravirine PK
Cmin ND parameters is seen.
Cmax ↔ 0.91 (0.58-1.42) INTELENCE and didanosine
etravirine can be used without dose
AUC ↔ 1.11 (0.99-1.25) adjustments.
Cmin ↔ 1.05 (0.93-1.18)
Cmax ↔ 1.16 (1.02-1.32)
Tenofovir disoproxil tenofovir No significant effect on
245 mg once dailyb AUC ↔ 1.15 (1.09-1.21) tenofovir and etravirine PK
Cmin ↑ 1.19 (1.13-1.26) parameters is seen.
Cmax ↑ 1.15 (1.04-1.27) INTELENCE and tenofovir
etravirine can be used without dose
AUC ↓ 0.81 (0.75-0.88) adjustments.
Cmin ↓ 0.82 (0.73-0.91)
Cmax ↓ 0.81 (0.75-0.88)
Other NRTIs Not studied, but no interaction expected based INTELENCE can be used
on the primary renal elimination route for other with these NRTIs without
NRTIs (e.g., abacavir, emtricitabine, dose adjustment.
lamivudine, stavudine and zidovudine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir disoproxil (HOS-108843) tenofovir (HOS-088083) abacavir (HOS-088077) emtricitabine (HOS-085840) lamivudine (HOS-085829) stavudine (HOS-088080) zidovudine (HOS-085837) didanosine (HOS-085836)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-08-13T16:37:00Z · SHA-256 b6b2c3fd3d600c0f1fd17ddc8f6c1da50bcb8b2181089113d0397c5ec46864c4 · Passage f29152615b96440b7358c56a91ccfc38d2ce96481ae99b250502680fed6f7a18 · Zeichen 1742–3928 im Abschnitt
Wechselwirkungen · Triumeq
Triumeq 50 mg/600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-129249 · Präparat HOS-096703
Emtricitabine, didanosine, Interaction not studied Triumeq is not recommended for use in
stavudine, zidovudine. combination with emtricitabine
containing products, since both
lamivudine (in Triumeq) and
emtricitabine are cytidine analogues (i.e.
risk for intracellular interactions, (see
section 4.4))
Protease inhibitors
Atazanavir/Dolutegravir Dolutegravir ↑ No dose adjustment is necessary.
AUC ↑ 91%
Cmax ↑ 50%
Cτ ↑ 180%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): emtricitabine (HOS-085840) didanosine (HOS-085836) stavudine (HOS-088080) zidovudine (HOS-085837) protease (HOS-085623) atazanavir (HOS-086180)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage 3bf10bb4dbff2b9e9a1f2913477a1a9b99c0f91eb5eef71b2dcdb54e9afc81f8 · Zeichen 10865–11769 im Abschnitt
Wechselwirkungen · Triumeq
Triumeq 5 mg/60 mg/30 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 47
HOS-129348 · Präparat HOS-096703
Emtricitabine, didanosine, Interaction not studied Triumeq is not recommended for use in
stavudine, zidovudine. combination with emtricitabine
containing products, since both
lamivudine (in Triumeq) and
emtricitabine are cytidine analogues (i.e.
risk for intracellular interactions, (see
section 4.4))
Protease inhibitors
Atazanavir/Dolutegravir Dolutegravir ↑ No dose adjustment is necessary.
AUC ↑ 91%
Cmax ↑ 50%
Cτ ↑ 180%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): emtricitabine (HOS-085840) didanosine (HOS-085836) stavudine (HOS-088080) zidovudine (HOS-085837) protease (HOS-085623) atazanavir (HOS-086180)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage 3bf10bb4dbff2b9e9a1f2913477a1a9b99c0f91eb5eef71b2dcdb54e9afc81f8 · Zeichen 9175–10079 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-134477 · Präparat HOS-097580
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Geometric mean change Recommendations concerning co-
therapeutic areas (%) administration
HIV ANTIRETROVIRALS
Integrase strand transfer inhibitors
Dolutegravir dolutegravir AUC ↓ 22% dolutegravir Darunavir co-administered with low
C24h ↓ 38% dolutegravir Cmax ↓ 11% dose ritonavir and dolutegravir can
darunavir ↔* be used without dose adjustment.
* Using cross-study comparisons to
historical pharmacokinetic data
Raltegravir Some clinical studies suggest At present the effect of raltegravir
raltegravir may cause a modest on darunavir plasma concentrations
decrease in darunavir plasma does not appear to be clinically
concentrations. relevant. Darunavir co-administered
with low dose ritonavir and
raltegravir can be used without dose
adjustments.
Nucleo(s/t)ide reverse transcriptase inhibitors (NRTIs)
Didanosine didanosine AUC ↓ 9% Darunavir co-administered with low
400 mg once daily didanosine Cmin ND dose ritonavir and didanosine can
didanosine Cmax ↓ 16% be used without dose adjustments.
darunavir AUC ↔ Didanosine is to be administered on
darunavir Cmin ↔ an empty stomach, thus it should be
darunavir Cmax ↔ administered 1 hour before or 2
hours after darunavir/ritonavir given
with food.
Tenofovir disoproxil tenofovir AUC ↑ 22% Monitoring of renal function may
245 mg once daily‡ tenofovir Cmin ↑ 37% be indicated when darunavir co-
tenofovir Cmax ↑ 24% administered with low dose
#
darunavir AUC ↑ 21% ritonavir is given in combination
#
darunavir Cmin ↑ 24% with tenofovir disoproxil,
#
darunavir Cmax ↑ 16% particularly in patients with
underlying systemic or renal
(↑ tenofovir from effect on MDR-1
disease, or in patients taking
transport in the renal tubules)
nephrotoxic agents.
Emtricitabine/tenofovir Tenofovir alafenamide ↔ The recommended dose of
alafenamide Tenofovir ↑ emtricitabine/tenofovir alafenamide
is 200/10 mg once daily when used
with darunavir with low dose
ritonavir.
Abacavir Not studied. Based on the different Darunavir co-administered with low
Emtricitabine elimination pathways of the other dose ritonavir can be used with
Lamivudine NRTIs zidovudine, emtricitabine, these NRTIs without dose
Stavudine stavudine, lamivudine, that are adjustment.
Zidovudine primarily renally excreted, and
abacavir for which metabolism is not
mediated by CYP450, no interactions
are expected for these medicinal
compounds and darunavir co-
administered with low dose ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir alafenamide (HOS-110476) tenofovir disoproxil (HOS-108843) abacavir (HOS-088077) tenofovir (HOS-088083) lamivudine (HOS-085829) emtricitabine (HOS-085840) dolutegravir (HOS-089992) ritonavir (HOS-084521) raltegravir (HOS-086187) didanosine (HOS-085836) zidovudine (HOS-085837) stavudine (HOS-088080)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage ccba4214faa97b5376d4e4a8ce74635a775924857bc2c674b7028ff519f04d29 · Zeichen 4790–9569 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 50–51
HOS-134609 · Präparat HOS-097580
50
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Recommendations concerning co-
therapeutic areas Geometric mean change (%) administration
Nucleo(s/t)ide reverse transcriptase inhibitors (NRTIs)
Didanosine didanosine AUC ↓ 9% Boosted darunavir and didanosine
400 mg once daily didanosine Cmin ND can be used without dose
didanosine Cmax ↓ 16% adjustments.
darunavir AUC ↔ Didanosine is to be administered on
darunavir Cmin ↔ an empty stomach, thus it should be
darunavir Cmax ↔ administered 1 hour before or 2 hours
after boosted darunavir given with
food.
Tenofovir disoproxil 245 mg tenofovir AUC ↑ 22% Monitoring of renal function may be
once daily‡ tenofovir Cmin ↑ 37% indicated when boosted darunavir is
tenofovir Cmax ↑ 24% given in combination with tenofovir
#
darunavir AUC ↑ 21% disoproxil, particularly in patients
#
darunavir Cmin ↑ 24% with underlying systemic or renal
#
darunavir Cmax ↑ 16% disease, or in patients taking
nephrotoxic agents.
(↑ tenofovir from effect on MDR-1
transport in the renal tubules)
Darunavir co-administered with
cobicistat lowers the creatinine
clearance. Refer to section 4.4 if
creatinine clearance is used for dose
adjustment of tenofovir disoproxil.
Emtricitabine/tenofovir Tenofovir alafenamide ↔ The recommended dose of
alafenamide Tenofovir ↑ emtricitabine/tenofovir alafenamide
is 200/10 mg once daily when used
with boosted darunavir.
Abacavir Not studied. Based on the different Boosted darunavir can be used with
Emtricitabine elimination pathways of the other these NRTIs without dose
Lamivudine NRTIs zidovudine, emtricitabine, adjustment.
Stavudine stavudine, lamivudine, that are
Zidovudine primarily renally excreted, and Darunavir co-administered with
abacavir for which metabolism is cobicistat lowers the creatinine
not mediated by CYP450, no clearance. Refer to section 4.4 if
interactions are expected for these creatinine clearance is used for dose
medicinal compounds and boosted adjustment of emtricitabine or
darunavir. lamivudine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): emtricitabine (HOS-085840) tenofovir alafenamide (HOS-110476) didanosine (HOS-085836) tenofovir disoproxil (HOS-108843) tenofovir (HOS-088083) cobicistat (HOS-088111) creatinine (HOS-086273) abacavir (HOS-088077) lamivudine (HOS-085829) zidovudine (HOS-085837) stavudine (HOS-088080)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 12f10221f64cd5bd996c35b7dbe8c441b3a4283b2a2e058c57f14f12c78125d7 · Zeichen 9327–13171 im Abschnitt
Wechselwirkungen · Dovato
Dovato 50 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-142822 · Präparat HOS-098886
7
Nevirapine/Dolutegravir Dolutegravir The recommended dose of dolutegravir
(Not studied, a similar is 50 mg twice daily when
reduction in exposure as co-administered with nevirapine. As
observed with efavirenz is Dovato is a fixed-dose tablet, an
expected, due to additional 50 mg tablet of dolutegravir
induction) should be administered, approximately
12 hours after Dovato for the duration of
the nevirapine co-administration (a
separate formulation of dolutegravir is
available for this dose adjustment, see
section 4.2).
Rilpivirine/Dolutegravir Dolutegravir No dose adjustment is necessary.
AUC 12%
Cmax 13%
Cτ 22%
Rilpivirine
Nucleoside reverse transcriptase inhibitors (NRTIs)
Tenofovir disoproxil Dolutegravir No dose adjustment is necessary when
AUC 1% Dovato is combined with tenofovir,
Cmax 3% didanosine, stavudine or zidovudine.
Cτ 8%
Tenofovir Dovato is not recommended for use in
combination with emtricitabine
containing products, since both
Emtricitabine, didanosine, Interaction not studied lamivudine (in Dovato) and
stavudine, tenofovir emtricitabine are cytidine analogues (i.e.
alafenamide, zidovudine risk for intracellular interactions), see
section 4.4.
Protease inhibitors
Atazanavir/Dolutegravir Dolutegravir No dose adjustment is necessary.
AUC 91%
Cmax 50%
C 180%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): emtricitabine (HOS-085840) protease (HOS-085623) atazanavir (HOS-086180) didanosine (HOS-085836) stavudine (HOS-088080) zidovudine (HOS-085837) nevirapine (HOS-088064) efavirenz (HOS-087947) rilpivirine (HOS-088090) tenofovir disoproxil (HOS-108843) tenofovir (HOS-088083)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T01:22:00Z · SHA-256 9ebb38c4be2b7abc7ba2934afb44e75aa1d6b86e46ecc069e568b333119de792 · Passage 3a54b7ec17f478707f317729fc54112d075d89e9ca126df050e9dd9dc88cd6d2 · Zeichen 7977–10650 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.